Compare Freeport-McMoRan Inc (FCX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs GSK plc — how do they compare? Freeport-McMoRan Inc trades at $73.17 (market cap $102.16B), while GSK plc trades at $46.41 (market cap $91.88B). The key difference: Freeport-McMoRan Inc and GSK plc are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and GSK plc for 93 Days on average.
| FCX | GSK | |
|---|---|---|
Market Cap | $102.16B | $91.88B |
Volume | 9,047,971 | 7,730,529 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $61.18 |
52-Week Low | $38.65 | $43.24 |
Typical Hold Time | 69 Days | 93 Days |
Enterprise Value | $108.44B | $111.88B |
Dividend Yield | 0.84% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.87, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $73.27. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $25.92 billion, with net income of $2.20 billion and a net margin of 11.38%. Recent news highlights strong copper demand driven by AI and data center growth, positioning FCX to benefit from favorable market trends.
The outlook for FCX is positive, supported by robust copper demand and expansion projects, but risks include rising production costs and potential regulatory investigations. Analyst sentiment is predominantly bullish, with 61% recommending buy. The stock offers growth potential from commodity tailwinds, though investors should monitor cost pressures and execution of growth initiatives.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
